Key clinical point: Dupilumab showed an acceptable safety profile and sustained efficacy through 4 years in adults with moderate-to-severe atopic dermatitis (AD).
Major finding: At 4 years, the exposure-adjusted incidence rate of treatment emergent adverse events (TEAE) was 256.86 events/100 patient-years, with most events being mild to moderate in severity. At least one serious and severe TEAE was experienced by 10.4% and 9.8% of patients in two dose categories. At week 204, the mean Eczema Area and Severity Index (EASI) score improved by 91.07%, with patients switching from 300 mg dupilumab weekly to every-2-weeks dosing while maintaining EASI scores up to 48 weeks post-transition.
Study details: Findings are from an interim analysis of the ongoing phase 3, LIBERTY AD open-label extension study including 2677 adults with moderate-to-severe AD who received 300 mg dupilumab weekly or every 2 weeks in previous phase 1-3 AD trials.
Disclosures: This study was funded by Sanofi and Regeneron Pharmaceuticals, Inc. Seven authors declared being employees or shareholders of Regeneron Pharmaceuticals or Sanofi, and other authors reported ties with various sources.
Source: Beck LA et al. Dupilumab provides acceptable safety and sustained efficacy for up to 4 years in an open-label study of adults with moderate-to-severe atopic dermatitis. Am J Clin Dermatol. 2022 (May 3). Doi: 10.1007/s40257-022-00685-0